Femasys gets FDA clearance to market FemaSeed

Femasys “announced it has received 510(k) Clearance from the United States Food and Drug Administration for FemaSeed(R), an innovative infertility treatment designed to deliver sperm directly to where conception occurs in a woman’s fallopian tube. In recent decades, infertility has affected an increasing number of women – estimated at 10 million in the United States according to the Center for Disease Control. Despite incremental advancements, there have been no recent meaningful affordable options. FemaSeed Intratubal Insemination is a type of an intrauterine insemination procedure that is less invasive than in vitro fertilization or intracytoplasmic sperm injection, which we expect would reduce the chances of procedural complications.”